All In Biotech

Investigational drug · Phase 2

OR502

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer, Tumor, Solid, Malignant Neoplasm.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "OR502"

First trial start

2023

Oct 24, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "OR502", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cancer
  • Tumor, Solid
  • Malignant Neoplasm
  • Metastatic Cancer
  • Advanced Solid Tumor
  • Cutaneous Melanoma
  • Non-small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "OR502" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Cancer

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • DivarasibGDC-6036, RO7435846Phase 38 trials

    Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer

  • IpatasertibRO5532961, GDC-0068Phase 35 trials

    Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer

  • anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials

    Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult

  • EmactuzumabPhase 32 trials

    Roche (Genentech) · Cancer, TGCT

  • GFH276Phase 25 trials

    Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)

  • ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials

    MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.